NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01964170,A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer,https://clinicaltrials.gov/study/NCT01964170,,COMPLETED,To compare the efficacy and safety of ASP3550 to goserelin acetate in patients with prostate cancer.,NO,Prostate Cancer,DRUG: degarelix|DRUG: Goserelin,"Cumulative castration rate of treatment in terms of serum testosterone level, Up to one year of the treatment","Proportion of castrated subjects in terms of serum testosterone level, Up to one year of the treatment|Proportion of castrated subjects in terms of serum testosterone level, Baseline and Days 3, 7, and 28|Changes in serum levels of prostate-specific antigen (PSA) over time, Up to one year of the treatment|Safety assessed by the incidence of adverse events, up to the end of treatment. approximately for 2 years",,Astellas Pharma Inc,,MALE,"ADULT, OLDER_ADULT",PHASE3,234,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,3550-CL-0010,2013-08-13,2015-06-05,2016-08-08,2013-10-17,,2024-10-31,"Chubu, Japan|Chugoku, Japan|Hokkaido, Japan|Kansai, Japan|Kantou, Japan|Kyushu, Japan|Shikoku, Japan|Touhoku, Japan",
